Results 71 to 80 of about 1,796 (140)

Bioenhancer Assessment of Black Pepper with Turmeric on Self-Reported Pain Ratings in Adults: A Randomized, Cross-Over, Clinical Trial. [PDF]

Nutrients
Durham L, Oster RA, Ithurburn M, Reynolds C, Hill JO, Smith DL.   +5 more
europepmc   +1 more source

Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]

Pediatr Pulmonol
Hinton AC, Sears EH, Lopez-Pintado S, Zuckerman JB.   +3 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Truong NH, Benaboud S, Bouazza N, Deneuville E, Mornand A, Reix P, Ribault M, Burgel PR, Froelicher-Bournaud L, Rouillon S, Sanoufi MR, Lui G, Urien S, Tréluyer JM, Sermet-Gaudelus I, Foissac F, Modul‐CF study group.   +16 more
europepmc   +1 more source

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A Retrospective Study. [PDF]

BJOG
Scott R, Downes A, Weitnauer L, Dobra R, Singh N, Robinson R, Diable E, Collins S, Bowman E, Tobin T, Jones A, Simmonds N, Felton I.   +12 more
europepmc   +1 more source

Understanding beliefs about elexacaftor-tezacaftor-ivacaftor therapy in adults living with cystic fibrosis. [PDF]

BMJ Open Respir Res
O'Leary C, Vinh A, Lea-Davies M, Weinman J, Horne R, Duckers J.   +5 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

J Pediatr Gastroenterol Nutr
Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, Nangui A, Deelawon A, Rave J, Dabelow S, Barucha A, Zagoya C, Duckstein F, Mainz JG.   +13 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [PDF]

Int J Mol Sci
Huang Y, Gonzales Cordova JM, Penrod S, Bendy LL, Cheng PC, Sanders DB, Davis MD, Gaston B, Chmiel JF.   +8 more
europepmc   +1 more source

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kogias C, Sopiadou A, Fouzas S, Vantsi P, Chrysochoou EA, Desli E, Galogavrou M, Gasparis N, Hatziagorou E.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mechanism of the metabolism of 1,3-benzodioxoles to carbon monoxide

Biochemical Pharmacology, 1984
Carbon monoxide is a minor product formed during the cytochrome P-450-catalyzed oxidation of 1,3-benzodioxoles. Studies with [2-13C]methylene 1,3-benzodioxoles established that the methylenic carbon of the 1,3-benzodioxole ring is the source of the carbon atom in the carbon monoxide, and an isotope effect of 1.7 to 2.0 was observed with [2-2H2 ...
M W Anders, Christopher F Wilkinson, C F Wilkinson   +2 more
exaly   +3 more sources